These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2389944)

  • 21. [Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period].
    Mizuno H; Ninomiya N; Ohta H; Tokoro K; Yasuma A; Ohnishi K; Ikeda Y
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2286-91. PubMed ID: 6639091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1989 Nov; 43(5):385-8. PubMed ID: 2612611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)].
    Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M
    Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966
    [No Abstract]   [Full Text] [Related]  

  • 26. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The efficacy of polychemotherapy programs in treating multiple myeloma patients].
    Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA
    Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
    Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
    Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)].
    Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y
    Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278
    [No Abstract]   [Full Text] [Related]  

  • 30. [Four cases of therapy-related leukemia in multiple myeloma].
    Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
    Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved survival in multiple myeloma with combination chemotherapy and plasmapheresis.
    Wahlin A; Holm J; Nyström L
    Haematologia (Budap); 1984; 17(4):465-71. PubMed ID: 6532916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
    Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
    J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K; Anger G
    Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal S; Powles R; Sirohi B; Treleaven J; Kulkarni S; Mehta J
    Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.